Oncobit set for growth after CHF 1.9 million capital increase

Oncobit AG has secured over CHF 1.9 million in a new financing round. The additional capital will support the company's clinical developments and broaden its reach into new markets.

Oncobit, a precision oncology company developing next-generation cancer monitoring solutions, has bolstered its financial base through a new capital increase backed by existing and new investors, including private business angels and strategic partner ID Solutions (IDS). The funding reinforces the company’s capacity to advance clinical validation work, progress with regulatory requirements, and continue its commercialization plans. It also positions Oncobit to further expand its portfolio into additional cancer indications and enter new markets, drawing on its IVDR and ISO 13485 certifications and its network of clinical and industry partners.

Founded in 2018 as a spinoff from the University of Zurich, a Venture Kick funding recipient and a Venture Leaders Medtech participant, Oncobit has built a scalable, data-driven cancer monitoring platform designed to detect cancer-related markers in liquid biopsies with high sensitivity and quantitative precision. With a focus on clinically relevant biomarkers and the use of advanced technology, the company offers cost-efficient and time-efficient tools that allow for close monitoring of a patient’s condition and support informed therapy decisions.

The company’s cloud-based software for data analysis and interpretation, trained on both healthy and patient datasets, provides consistent and robust result reporting. Oncobit’s diagnostic solutions are now used by an expanding group of pharmaceutical companies, clinical laboratories, and hospital institutions.


Oncobit's team